logo
AXSM_logo
AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing dextromethorphan HBr (45 mg) and bupropion HCl (105 mg). The dextromethorphan component of AUVELITY is an antagonist of the NMDA receptor (an ionotropic glutamate receptor) and a sigma-1 receptor agonist

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, the rest of the management team, along with other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Thursday, October 27, 2022, to commemorate the availability of AUVELITY™ in the United States by prescription

By Axsome Therapeutics, Inc.
Published - Oct 27, 2022, 07:07 AM ET
Last Updated - Apr 24, 2024, 02:29 PM EDT

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, the rest of the management team, along with other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Thursday, October 27, 2022, to commemorate the availability of AUVELITY™ in the United States by prescription.

“This is a momentous time in Axsome’s history as we have now launched Auvelity. With the relaunch of Sunosi we are now making available to patients two treatments for mental conditions,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We are honored to ring NASDAQ’s opening bell to commemorate the availability of Auvelity by prescription and the hard work and dedication of the Axsome team which made it possible. Axsome’s commitment to discovering, developing, and delivering new treatments for those living with mental health conditions remains firm as we continue to advance the rest of our robust pipeline.”

The ceremony will take place at the Nasdaq MarketSite, 4 Times Square, New York, NY. The live ceremonies will begin at 9:20 AM Eastern Time and can be viewed at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

About AUVELITY™

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024